Earnings Call Summary | Simulations Plus(SLP.US) Q3 2024 Earnings Conference
Earnings Call Summary | Simulations Plus(SLP.US) Q3 2024 Earnings Conference
The following is a summary of the Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript:
以下是Simulations Plus, Inc. (SLP) Q3 2024業績會議事要點:
Financial Performance:
金融業績：
Q3 FY2024 total revenue increased 14% to $18.5 million.
Software revenue increased 12%, while Services revenue increased 18%.
Gross margin for Q3 was 71%, down from 82% last year, mainly due to a shift in Services personnel to cost of revenue.
Net income for Q3 was $3.1 million, representing a decrease from the previous year.
Diluted earnings per share were $0.15, and adjusted diluted earnings per share were $0.19.
Q3 FY2024總營業收入增長14%至1850萬美元。
軟件收入增長12%，而服務業收入增長18%。
Q3的毛利率爲71%，較去年的82%下降，主要原因是服務人員轉爲收入成本。
Q3的淨利潤爲310萬美元，與上一年相比有所下降。
稀釋每股收益爲0.15美元，調整後的稀釋每股收益爲0.19美元。
Business Progress:
業務進展：
Launched GPX, a new generation software for pharmacokinetics modeling, receiving positive initial client reactions.
Announced the acquisition of Pro-ficiency, expanding offerings across the drug development continuum.
Experiencing solid bookings and a healthy pipeline, with a backlog of $19.6 million.
Anticipate revenue from backlog within the next 12 months to increase to approximately 91%.
推出了藥動學建模的新一代軟件GPX，獲得了客戶的積極反饋。
宣佈收購Pro-ficiency，擴展了整個藥品開發過程中的業務範圍。
有穩固的預訂和健康的銷售渠道，積壓訂單總額爲1960萬美元。
預計未來12個月內來自積壓訂單的營業收入會增加至大約91%。
Opportunities:
機會：
Continued recovery in biotech funding presents opportunities for increased revenue, particularly with Pro-ficiency integration.
Market improvements and a positive shift in biotech funding environments may boost future bookings and revenue.
生物技術資金的持續恢復爲增加收入提供了機會，特別是在和Pro-ficiency的整合中。
市場的改善和生物技術資金環境的積極變化可能會推動未來預訂單和收入的增長。
Risks:
風險：
Variable spending patterns among large pharmaceutical clients reflect continued market caution, potentially impacting revenue consistency.
Delays in client source data affecting PBPK services could disrupt expected revenue flow.
大型製藥客戶不確定性的變動可能會影響收入的穩定性。
客戶數據採集延遲可能會干擾預期的藥代動力學服務營收。
More details: Simulations Plus IR
更多詳情：Simulations Plus IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。